SCHEMBL21247413

SCHEMBL21247413

COC(=O)c1c(C2=Cc3ccccc3CC2)csc1NC(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ MAPK10 P53779 2/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ POLB P06746 3/20 0.38
▸ TDP1 Q9NUW8 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 7/20 0.37
▸ TP53 P04637 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ HTT P42858 1/20 0.36
▸ THRB P10828 2/20 0.35
▸ HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26327177 0.80 EPHX2 (0.49) CNR2EPHX2MAPK10MAPK8MAPK9
SCHEMBL3714075 0.79 EPHX2 (0.48) CNR2EPHX2ALDH1A1POLBTDP1
SCHEMBL30001282 0.78 EPHX2 (0.47) EPHX2MAPK10MAPK8MAPK9ALDH1A1
SCHEMBL29446051 0.78 EPHX2 (0.47) CNR2EPHX2ALDH1A1POLBTDP1
SCHEMBL19260383 0.78 EPHX2 (0.47) CNR2EPHX2ALDH1A1POLBTDP1
SCHEMBL23412767 0.78 EPHX2 (0.47) EPHX2MAPK10MAPK8MAPK9ALDH1A1
SCHEMBL21247460 0.74 ALDH1A1 (0.59) ALDH1A1TDP1LMNAKMT2AMAPT
SCHEMBL23413466 0.72 FABP5 (0.47) EPHX2ALDH1A1LMNAPKMKMT2A
SCHEMBL30000091 0.72 FABP5 (0.47) EPHX2ALDH1A1LMNAPKMKMT2A
SCHEMBL21247379 0.71 EPHX2 (0.41) CNR2EPHX2ALDH1A1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767316-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-09-26 — — US disclosed
US-20210040059-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES Institut National de la Santé et de la Recherche Médicale (FR) 2021-02-11 — — US disclosed
EP-3749650-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
CN-111936471-A Non-fused thiophene derivative and use thereof 埃尼奥制药公司 2020-11-13 — — CN disclosed
WO-2019154956-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040059-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH CNR2 4386/4885EPHX2 3705/4885MAPK10 4060/4885
US-11767316-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH CNR2 4386/4885EPHX2 3705/4885MAPK10 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback